BAP1 and nonpapillary renal cell carcinoma: Radiogenomics is poised to revolutionize ccRCC management by enabling the non-invasive prediction of genetic mutations and molecular subtypes through imaging features, as demonstrated by models achieving high accuracy in identifying mutations such as von Hippel–Lindau (VHL) and BRCA1-associated protein-1 (BAP1) [20].